
The global neurofibromatosis market size was valued at USD 14.60 billion in 2024 and is expected to reach USD 36.66 billion by 2032, at a CAGR of 12.20% during the forecast period
The market growth is largely fueled by the increasing prevalence of genetic disorders and rare diseases, driving demand for effective neurofibromatosis therapies and management solutions
Furthermore, advancements in targeted therapies, growing investments in research and development, and rising awareness among patients and healthcare providers are accelerating the uptake of neurofibromatosis solutions, thereby significantly boosting the industry's growth

